We are live on ! Find out more
ASND icon

Ascendis Pharma A/S

26 hedge funds and large institutions have $223M invested in Ascendis Pharma A/S in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

21% more capital invested

Capital invested by funds: $185M → $223M (+$38.4M)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

4% more funds holding

Funds holding: 2526 (+1)

Holders
26
Holders Change
+1
Holders Change %
+4%
% of All Funds
0.69%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
3
Increased
7
Reduced
6
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$42.6M -$254K -14,300 -0.6%
RCM
2
RA Capital Management
Massachusetts
$40.1M +$8.7M +489,919 +29%
VC
3
Vivo Capital
California
$26.3M +$25.2M +1,419,332 New
VAM
4
Visium Asset Management
New York
$26.1M +$663K +37,350 +3%
RIM
5
RS Investment Management
California
$18.3M +$121K +6,788 +0.7%
VMI
6
VHCP Management II
New York
$13.4M
JHIU
7
Janus Henderson Investors US
Colorado
$12.4M -$567K -31,909 -5%
ACP
8
Acuta Capital Partners
California
$11.6M +$1.85M +104,388 +20%
BBA
9
Baker Bros. Advisors
New York
$9.38M
RSCM
10
Rock Springs Capital Management
Maryland
$5.01M
O
11
OrbiMed
New York
$4.12M
Lazard Asset Management
12
Lazard Asset Management
New York
$3.58M
SCM
13
Sio Capital Management
New York
$3.47M -$1.73M -97,565 -34%
VM
14
VHCP Management
New York
$1.67M
CAM
15
Cormorant Asset Management
Massachusetts
$1.14M
DCM
16
DAFNA Capital Management
California
$988K
SAM
17
Sectoral Asset Management
Quebec, Canada
$577K
PAMU
18
Pictet Asset Management (UK)
United Kingdom
$540K
AA
19
ALPS Advisors
Colorado
$524K -$86K -4,843 -15%
Morgan Stanley
20
Morgan Stanley
New York
$478K +$407K +22,908 +804%
Bank of America
21
Bank of America
North Carolina
$414K +$25.8K +1,452 +7%
GCP
22
GSA Capital Partners
United Kingdom
$347K +$332K +18,700 New
CS
23
Credit Suisse
Switzerland
$186K -$21.4K -1,204 -11%
UBS Group
24
UBS Group
Switzerland
$26K +$231 +13 +0.9%
Deutsche Bank
25
Deutsche Bank
Germany
$1K -$75.3K -4,239 -98%

ASND Hedge Fund Activity: Q1 2016 in Review

26 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2016, worth a combined $223M — up 21% from $185M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ASND positions and 2 closed out — a net gain of 1 holder — while 7 added to existing stakes and 6 trimmed.

The largest buyer was RA Capital Management, adding an estimated $8.7M. The largest seller was Sio Capital Management, cutting an estimated $1.73M.

  • 26 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2016, up from 25 in Q4 2015.
  • Funds reported $223M of Ascendis Pharma A/S stock for Q1 2016, up 21% quarter-over-quarter.
  • 3 funds opened new Ascendis Pharma A/S positions in Q1 2016 and 2 closed out, a net change of +1 holder.
  • The largest Ascendis Pharma A/S buyer in Q1 2016 was RA Capital Management, an estimated $8.7M added.
  • The largest Ascendis Pharma A/S seller in Q1 2016 was Sio Capital Management, an estimated $1.73M sold.

Based on aggregated 13F filings for Q1 2016.